Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the ...

Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, ...

Fintel reports that on July 23, 2025, BMO Capital downgraded their outlook for Replimune Group (NasdaqGS:REPL) from Outperform to Underperform. Analyst Price Forecast Suggests 595.73% Upside As of ...

Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Replimune Group, Inc. (NASDAQ: REPL) resulting from ...

View the latest Replimune Group Inc. (REPL) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Texas Instruments stock is an attractive buying opportunity, even after its rally this year, according to TD Cowen.

Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response.

WOBURN, Mass., July 11, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...

Investing.com - H.C. Wainwright has reiterated its Buy rating and $22.00 price target on Replimune Group (NASDAQ: REPL), currently trading at $9.40, as the company approaches a key regulatory decision ...